Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-Small Cell Lung Cancer Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Perspective (2018-2033)
2.2 Drugs for Non-Small Cell Lung Cancer Growth Trends by Region
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2018-2023)
2.2.3 Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2024-2033)
2.3 Drugs for Non-Small Cell Lung Cancer Market Dynamics
2.3.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
2.3.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue (2018-2023)
3.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Non-Small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-Small Cell Lung Cancer Revenue in 2022
3.5 Drugs for Non-Small Cell Lung Cancer Key Players Head office and Area Served
3.6 Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
3.7 Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2018-2023)
4.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2024-2033)
5 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2018-2023)
5.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2018-2033)
6.2 North America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023)
6.4 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2018-2033)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023)
7.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2018-2033)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2023)
8.4 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2018-2033)
9.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023)
9.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2018-2033)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023)
10.4 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.2.5 GlaxoSmithKline Recent Development
11.3 Menarini
11.3.1 Menarini Company Detail
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.3.5 Menarini Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Detail
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.5.5 Ziopharm Oncology Recent Development
11.6 Alchemia
11.6.1 Alchemia Company Detail
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.6.5 Alchemia Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.7.5 Amgen Recent Development
11.8 Apotex
11.8.1 Apotex Company Detail
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.8.5 Apotex Recent Development
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Detail
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.9.5 BioMarin Pharmaceutical Recent Development
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Detail
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.10.5 CellAct Pharma Recent Development
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Detail
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.11.5 Cerulean Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Detail
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.12.5 Cipla Recent Development
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Detail
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.13.5 Cornerstone Pharmaceuticals Recent Development
11.14 Curis
11.14.1 Curis Company Detail
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.14.5 Curis Recent Development
11.15 CytRx
11.15.1 CytRx Company Detail
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.15.5 CytRx Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Detail
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.16.5 Eli Lilly Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Detail
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.17.5 Exelixis Recent Development
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Detail
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.18.5 Fresenius Kabi Recent Development
11.19 Genentech
11.19.1 Genentech Company Detail
11.19.2 Genentech Business Overview
11.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
11.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.19.5 Genentech Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Detail
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Hospira
11.21.1 Hospira Company Detail
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.21.5 Hospira Recent Development
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Detail
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.22.5 Intas Pharmaceuticals Recent Development
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Detail
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.23.5 Karyopharm Therapeutics Recent Development
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Detail
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.24.5 Kyowa Hakko Kirin Recent Development
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Detail
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
11.25.5 Ligand Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Radiofrequency Ablation (RFA)
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Targeted Therapies
Table 6. Key Players of Immunotherapy
Table 7. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region (2018-2023)
Table 11. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region (2024-2033)
Table 13. Drugs for Non-Small Cell Lung Cancer Market Trends
Table 14. Drugs for Non-Small Cell Lung Cancer Market Drivers
Table 15. Drugs for Non-Small Cell Lung Cancer Market Challenges
Table 16. Drugs for Non-Small Cell Lung Cancer Market Restraints
Table 17. Global Drugs for Non-Small Cell Lung Cancer Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Drugs for Non-Small Cell Lung Cancer Market Share by Players (2018-2023)
Table 19. Global Top Drugs for Non-Small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2022)
Table 20. Ranking of Global Top Drugs for Non-Small Cell Lung Cancer Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
Table 24. Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type (2018-2023)
Table 28. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type (2024-2033)
Table 30. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Application (2018-2023)
Table 32. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Application (2024-2033)
Table 34. North America Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 49. Bristol-Myers Squibb Company Detail
Table 50. Bristol-Myers Squibb Business Overview
Table 51. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product
Table 52. Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 53. Bristol-Myers Squibb Recent Development
Table 54. GlaxoSmithKline Company Detail
Table 55. GlaxoSmithKline Business Overview
Table 56. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product
Table 57. GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 58. GlaxoSmithKline Recent Development
Table 59. Menarini Company Detail
Table 60. Menarini Business Overview
Table 61. Menarini Drugs for Non-Small Cell Lung Cancer Product
Table 62. Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 63. Menarini Recent Development
Table 64. Sanofi Company Detail
Table 65. Sanofi Business Overview
Table 66. Sanofi Drugs for Non-Small Cell Lung Cancer Product
Table 67. Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 68. Sanofi Recent Development
Table 69. Ziopharm Oncology Company Detail
Table 70. Ziopharm Oncology Business Overview
Table 71. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product
Table 72. Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 73. Ziopharm Oncology Recent Development
Table 74. Alchemia Company Detail
Table 75. Alchemia Business Overview
Table 76. Alchemia Drugs for Non-Small Cell Lung Cancer Product
Table 77. Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 78. Alchemia Recent Development
Table 79. Amgen Company Detail
Table 80. Amgen Business Overview
Table 81. Amgen Drugs for Non-Small Cell Lung Cancer Product
Table 82. Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 83. Amgen Recent Development
Table 84. Apotex Company Detail
Table 85. Apotex Business Overview
Table 86. Apotex Drugs for Non-Small Cell Lung Cancer Product
Table 87. Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 88. Apotex Recent Development
Table 89. BioMarin Pharmaceutical Company Detail
Table 90. BioMarin Pharmaceutical Business Overview
Table 91. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product
Table 92. BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 93. BioMarin Pharmaceutical Recent Development
Table 94. CellAct Pharma Company Detail
Table 95. CellAct Pharma Business Overview
Table 96. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product
Table 97. CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 98. CellAct Pharma Recent Development
Table 99. Cerulean Pharma Company Detail
Table 100. Cerulean Pharma Business Overview
Table 101. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product
Table 102. Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 103. Cerulean Pharma Recent Development
Table 104. Cipla Company Detail
Table 105. Cipla Business Overview
Table 106. Cipla Drugs for Non-Small Cell Lung Cancer Product
Table 107. Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 108. Cipla Recent Development
Table 109. Cornerstone Pharmaceuticals Company Detail
Table 110. Cornerstone Pharmaceuticals Business Overview
Table 111. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 112. Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 113. Cornerstone Pharmaceuticals Recent Development
Table 114. Curis Company Detail
Table 115. Curis Business Overview
Table 116. Curis Drugs for Non-Small Cell Lung Cancer Product
Table 117. Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 118. Curis Recent Development
Table 119. CytRx Company Detail
Table 120. CytRx Business Overview
Table 121. CytRx Drugs for Non-Small Cell Lung Cancer Product
Table 122. CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 123. CytRx Recent Development
Table 124. Eli Lilly Company Detail
Table 125. Eli Lilly Business Overview
Table 126. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product
Table 127. Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 128. Eli Lilly Recent Development
Table 129. Exelixis Company Detail
Table 130. Exelixis Business Overview
Table 131. Exelixis Drugs for Non-Small Cell Lung Cancer Product
Table 132. Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 133. Exelixis Recent Development
Table 134. Fresenius Kabi Company Detail
Table 135. Fresenius Kabi Business Overview
Table 136. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product
Table 137. Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 138. Fresenius Kabi Recent Development
Table 139. Genentech Company Detail
Table 140. Genentech Business Overview
Table 141. Genentech Drugs for Non-Small Cell Lung Cancer Product
Table 142. Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 143. Genentech Recent Development
Table 144. Hikma Pharmaceuticals Company Detail
Table 145. Hikma Pharmaceuticals Business Overview
Table 146. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 147. Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 148. Hikma Pharmaceuticals Recent Development
Table 149. Hospira Company Detail
Table 150. Hospira Business Overview
Table 151. Hospira Drugs for Non-Small Cell Lung Cancer Product
Table 152. Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 153. Hospira Recent Development
Table 154. Intas Pharmaceuticals Company Detail
Table 155. Intas Pharmaceuticals Business Overview
Table 156. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 157. Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 158. Intas Pharmaceuticals Recent Development
Table 159. Karyopharm Therapeutics Company Detail
Table 160. Karyopharm Therapeutics Business Overview
Table 161. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product
Table 162. Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 163. Karyopharm Therapeutics Recent Development
Table 164. Kyowa Hakko Kirin Company Detail
Table 165. Kyowa Hakko Kirin Business Overview
Table 166. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product
Table 167. Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 168. Kyowa Hakko Kirin Recent Development
Table 169. Ligand Pharmaceuticals Company Detail
Table 170. Ligand Pharmaceuticals Business Overview
Table 171. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 172. Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2018-2023) & (US$ Million)
Table 173. Ligand Pharmaceuticals Recent Development
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Non-Small Cell Lung Cancer Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type: 2022 VS 2033
Figure 3. Radiofrequency Ablation (RFA) Features
Figure 4. Radiation Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Targeted Therapies Features
Figure 7. Immunotherapy Features
Figure 8. Global Drugs for Non-Small Cell Lung Cancer Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application: 2022 VS 2033
Figure 10. Hospitals Case Studies
Figure 11. Clinics Case Studies
Figure 12. Other Case Studies
Figure 13. Drugs for Non-Small Cell Lung Cancer Report Years Considered
Figure 14. Global Drugs for Non-Small Cell Lung Cancer Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Drugs for Non-Small Cell Lung Cancer Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region: 2022 VS 2033
Figure 17. Global Drugs for Non-Small Cell Lung Cancer Market Share by Players in 2022
Figure 18. Global Top Drugs for Non-Small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2022
Figure 20. North America Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Drugs for Non-Small Cell Lung Cancer Market Share by Country (2018-2033)
Figure 22. United States Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Drugs for Non-Small Cell Lung Cancer Market Share by Country (2018-2033)
Figure 26. Germany Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Share by Region (2018-2033)
Figure 34. China Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Drugs for Non-Small Cell Lung Cancer Market Share by Country (2018-2033)
Figure 42. Mexico Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Share by Country (2018-2033)
Figure 46. Turkey Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 50. Menarini Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 51. Sanofi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 52. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 53. Alchemia Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 54. Amgen Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 55. Apotex Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 56. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 57. CellAct Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 58. Cerulean Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 59. Cipla Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 60. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 61. Curis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 62. CytRx Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 63. Eli Lilly Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 64. Exelixis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 65. Fresenius Kabi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 66. Genentech Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 67. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 68. Hospira Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 69. Intas Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 70. Karyopharm Therapeutics Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 71. Kyowa Hakko Kirin Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 72. Ligand Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed